News Headlines
-
Ardena Launches Online Biomarker Catalogue: 228 Markers, One Quote Request
10/29/2026
Ardena has launched a searchable Biomarker Catalogue on its website, giving sponsors a faster route from biomarker selection to a bioanalysis quote.
-
Global Partnership Including SK Bioscience Secures BARDA Funding To Advance Bundibugyo Ebola Vaccine Development And Manufacturing
10/29/2026
SK bioscience announced on 29 that it has joined forces with IAVI, a global nonprofit biomedical research organization, Hilleman Laboratories and other partners in a project supported by USD 36 million of a contract valued up to USD 99 million (approximately KRW 130 billion) from the Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), to advance development, manufacturing, and clinical evaluation of a Bundibugyo Ebola vaccine.
-
BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma And Hanmi Pharm For Investigational Next-Generation Enzyme Replacement Therapy, Adding A Second Potential Treatment For Fabry Disease
10/29/2026
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it has entered into an exclusive worldwide license agreement with GC Biopharma Corp. and Hanmi Pharm Co., Ltd. to develop and commercialize HM15421/GC1134A, an investigational long-acting enzyme replacement therapy for Fabry disease.
-
Celularity And Vesalius Longevity Labs Sign Exclusive Collaboration For Peptual® Peptide APIs Manufactured In The United States
10/29/2026
Celularity Inc. (“Celularity”), a longevity-focused regenerative and cellular medicine company, and Vesalius Longevity Labs Inc. (“Vesalius”), a leading, global peptide and longevity brand, today announced that they have entered into an exclusive manufacturing agreement to establish a dedicated, first-of-its-kind, U.S. final stage API manufacturing and supply platform for Vesalius’s Peptual-branded active pharmaceutical ingredients (“APIs”).
-
Nxera Pharma Secures Exclusive Rights To Fabry Disease Phase 3 Oral Therapy Candidate Lucerastat For Japan And Selected Asia Pacific Markets
10/28/2026
Nxera Pharma Co., Ltd. ("Nxera" or the "Company"; TSE: 4565) today announces that it has exercised its option to license lucerastat from Idorsia Ltd ("Idorsia"; SIX: IDIA) and has entered into a co-development and commercialization agreement (the "Agreement").
-
IAVI Awarded $36M From BARDA For Bundibugyo Virus Vaccine Development
10/28/2026
Today IAVI, a global nonprofit biomedical research organization, together with partners Hilleman Laboratories, SK bioscience, and IDT Biologika announced that IAVI has been awarded US $36Mof a contract valued up to US $99M from the Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, to advance development, manufacturing, and clinical evaluation of its one-dose vaccine candidate against Bundibugyo virus (BDBV), the cause of the ongoing Ebola epidemic in the Democratic Republic of the Congo (DRC).
-
Enthorin Therapeutics Announces License Agreement With Rumi Therapeutics For ENT-7340, For Fragile X Syndrome
10/28/2026
Enthorin Therapeutics, LLC today announced that it has entered into an option-to-license agreement with Rumi Therapeutics for ENT-7340, Enthorin’s IND-enabled phosphodiesterase 2A (PDE2A) inhibitor being developed for Fragile X syndrome (FXS) and other intellectual and developmental disabilities.
-
ABIONYX Pharma Finalizes The Structuring Of Its CER- 001 Bioproduction Chain Through A Strategic Partnership With AXPLORA, Marking A Major Milestone Toward Its Potential Commercialization
10/27/2026
ABIONYX Pharma, a next-generation biopharmaceutical company developing innovative treatmentsforsepsis and intensive care based on a proprietary apoA-I technology platform, today announced a strategic manufacturing partnership with AXPLORA, a global Contract Development and Manufacturing Organization (CDMO), to apply its specialist purification expertise to recombinant human apoA-I, the key biological component of CER-001, and support the next stages of the program’s development.
-
SynAct Pharma Signs First Commercial Partnership For Resomelagon With Leading Brazilian Pharmaceutical Company
10/27/2026
SynAct Pharma AB (publ) (”SynAct”), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach known as “pro-resolution”, today announced that it has entered into a strategic co-development and commercialization agreement with Hipolabor Farmacêutica LTDA (“Hipolabor”) for resomelagon in the treatment of dengue in Brazil, one of the world's largest markets for dengue treatment.
-
Astellas And Audax Biosciences Enter Exclusive Option And License Agreement For DAX-044, A Novel Immune-Targeted IL-12 Antibody-Cytokine Fusion For Immuno-Oncology
10/27/2026
Astellas Pharma Inc. [TSE: 4503, President and CEO: Naoki Okamura, "Astellas"] and Audax Biosciences Pty Ltd ("Audax") today announced that they have entered into an exclusive option and license agreement for DAX-044, Audax's lead immuno-oncology AVIKINE® candidate.